Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy
- 3 July 2008
- journal article
- research article
- Published by Taylor & Francis in Nucleosides, Nucleotides & Nucleic Acids
- Vol. 27 (6-7) , 585-591
Abstract
Clinical benefit early in urate-lowering treatment of gout is difficult to document. We examined data from 1,832 gouty subjects treated with either urate-lowering agents or placebo to identify determinants of gout flare incidence and tophus size during year 1 of treatment. Reductions from pretreatment serum urate levels influenced flare frequency and tophus size, but the effect of urate level on flare incidence was biphasic. Lower urate levels were associated with higher flare incidence early in treatment but lower incidence by one year. The complex relationship between urate-lowering and clinical outcome early in treatment has implications for both clinical and investigative approaches to urate-lowering management.Keywords
This publication has 7 references indexed in Scilit:
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidaseArthritis Research & Therapy, 2005
- A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapyArthritis Care & Research, 2004
- GoutNew England Journal of Medicine, 2003
- Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic goutArthritis Care & Research, 2002
- Optimal Range of Serum Urate Concentrations to Minimize Risk of Gouty Attacks During Anti-Hyperuricemic Treatment1998
- Asymptomatic hyperuricemia. Risks and consequences in the normative aging studyThe American Journal of Medicine, 1987